A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Voriconazole

Criteria

Inclusion Criteria:

• Systemic or invasive fungal infection

• Infection caused by organism for which there is no current treatment or infection with evidence of failure and/or intolerance to treatment with approved antifungal agents

Exclusion Criteria:

• Liver function test abnormalities

• Renal disease

• Fungal infections not considered to be invasive or systemic